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Despite their efficacy at controlling joint inflammation, current treatments of rheumatoid arthritis (RA) leave 
up to 40% of patients into non-remission. Non-remission, frequently due to persistently negative self-
reported impact of RA, was found to be associated with significant persistent depressive symptoms 6-7 
months after initiation of arthritis treatment. Mindfulness-Based Stress Reduction (MBSR) is proposed to 
improve depressive symptoms and RA-related clinical outcomes. To pave the way for an eventual 
randomized controlled trial, a feasibility and acceptability study of MBSR has been realized. 
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A standardized 8-week MBSR program was offered to groups of patients with controlled inflammatory 
disease but high levels of depressive symptoms. 
 
Qualitative interviews based on a theoretical framework of acceptability were conducted. Change in 
depressive symptoms (CES-D tool), fatigue and pain (SF-36), anxiety (GAD-7), pain, disease activity 
(PtVAS and SDAI scores) was measured over a 6-month period. 
 
RESULTS:  
27 patients have been recruited (3 distinct MBSR groups). Factors leading to a higher rate of success in 
recruitment were identified. Despite the small sample, the intervention was found to have a clear impact on 
depressive symptoms (p=0.004), anxiety (p=0.005), and social functioning (from the SF-36; p=0.04). 
Patients reported that MBSR gave them the opportunity to control their reactions in face of stressful 
situations. 
 
Perceptions were almost uniformly positive towards MBSR, and most appear to have integrated some part 
of the intervention in their daily life. 
 
CONCLUSIONS:  
Although recruitment was challenging, a MBSR trial on depressed patients with controlled inflammatory 
disease was found acceptable and feasible within this population. Preliminary clinical results showed 
positive impacts of such intervention.■ 
 
 
 
  
